Skip to main content

Table 1 Demographics and clinical variables according to radiographic progression at the 24-month follow up

From: Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study

 

All patients

No radiographic progression

Radiographic progression

P valuea

Number

149

131

18

 

 Age, years, mean (SD)

58.15 (12.58)

57.60 (12.71)

62.22 (11.01)

0.11

 Female, n (%)

123 (82.6)

108 (82.4)

15 (83.3)

0.61

 Disease duration, years, median (IQR)

13.00 (8.00; 21.00)

13.00 (8.00; 20.50)

13.50 (8.50; 30.75)

0.41

 Previous anti-TNFα failures, n (%)

30 (20.1)

26 (19.9)

4 (22.2)

0.51

 Positive ACPA and/or RF, n (%)

76 (51.0)

65 (49.6)

11 (61.1)

0.36

 Smokers or ex-smokers, n (%)

39 (26.2)

35 (26.7)

4 (22.2)

0.47

 TSS progression per year before baseline, median (IQR)

8.00 (5.00; 11.63)

7.32 (5.00; 11.10)

10.25 (7.38; 15.50)

0.02

 ADA treatments, n (%)

56 (37.6)

48 (36.6)

8 (44.4)

0.59

 ETA treatments, n (%)

93 (62.4)

83 (63.4)

10 (55.6)

0.59

 Low dose biologic, n (%)

103 (69.1)

89 (67.9)

14 (77.8)

0.40

 Concurrent DMARD use, n (%)

76 (51.0)

66 (50.4)

10 (55.6)

0.68

 PDN daily dose, mg, median (IQR)

1.00 (0.74; 2.00)

1.00 (0.60; 2.00)

1.50 (0.75; 2.00)

0.99

 TSS progression at the 24-month follow up, median (IQR)

0 (0)

0 (0)

2.00 (2.00; 14.00)

<0.01

Baseline

    

 HAQ, mean (SD)

0.74 (0.40)

0.73 (0.41)

0.87 (0.25)

0.08

 DAS28, median (IQR)

2.21 (1.92; 2.38)

2.24 (1.85; 2.38)

2.05 (2.05; 2.38)

0.53

 CRP, mg/L, median (IQR)

3.00 (1.00; 4.00)

3.00 (1.00; 4.00)

1.00 (1.00; 4.00)

0.24

 TJC, median (IQR)

1 (0; 2)

1 (0; 2)

1 (1; 1)

0.70

 SJC, median (IQR)

0 (0)

0 (0)

0 (0)

 Patient-VAS, mm, median (IQR)

20 (15; 20)

20 (10; 30)

20 (0)

0.23

Follow up, 24 months

    

 HAQ, median (IQR)

0.74 (0.39)

0.73 (0.40)

0.85 (0.23)

0.18

 DAS28, median (IQR)

2.16 (1.80; 2.43)

2.18 (1.80; 2.63)

1.85 (1.82; 2.42)

0.52

 CRP, mg/L, median (IQR)

2.00 (1.00; 3.00)

2.00 (1.00; 3.00)

2.00 (2.00; 3.00)

0.29

 TJC, median (IQR)

1 (0; 2)

1 (0; 2)

0 (0; 1)

0.24

 SJC, median (IQR)

0 (0)

0 (0)

0 (0)

 Patient-VAS, mm, median (IQR)

20 (10; 30)

20 (10; 30)

33 (28; 35)

0.01

Change between baseline and 24-month follow up

 HAQ, median (IQR)

0 (−0.10; 0.07)

0 (−0.11; 0.07)

0.01 (−0.05; 0.05)

0.56

 DAS28, mean (SD)

−0.13 (0.55)

0 (0.58)

−0.02 (0.30)

0.63

 CRP, mg/L, median (IQR)

0 (−2.00; −2.00)

0 (−3.00; 2.00)

1.00 (−1.00; 1.00)

0.11

 TJC, median (IQR)

0 (−1; −1)

0 (−1; −1)

−1 (−1; 0)

0.28

 SJC, median (IQR)

0 (0)

0 (0)

0 (0)

 Patient-VAS, mm, median (IQR)

5 (−5; 10)

0 (−10; 10)

13 (9; 15)

<0.01

  1. SD standard deviation, IQR interquartile range, TNFα tumor necrosis factor-α, ACPA anti-citrullinated peptides, RF rheumatoid factor, TSS total Sharp score, ADA adalimumab, ETA etanercept, DMARD disease-modifying anti-rheumatic drug, PDN prednisone, HAQ Health Assessment Questionnaire, DAS28 disease activity score in 28 joints, CRP C-reactive protein, TJC tender joint count in 28 joints, SJC swollen joint count in 28 joints, patient-VAS patient’s global health measured on a visual analog scale. aUnpaired t test was used to compare variables with a normal distribution, Mann-Whitney test was used to compare variables with a non-normal distribution. Quantitative measures were compared using the chi-square test or Fisher’s exact test